INS and chronic kidney disease: For patients with CKD progression, the majority (85.7%) of patients were on calcium channel blockers, 62.6% were on diuretics, 57.1% were on statins, 55.1% were on beta blockers, 31.3% were on insulin, 29.3% and were on aspirin.